School of Medicine


Showing 1-10 of 16 Results

  • Arghavan Salles

    Arghavan Salles

    Clinical Associate Professor, Medicine - Gastroenterology & Hepatology

    BioDr. Salles is a minimally invasive and bariatric surgeon. She completed medical school and residency in general surgery at Stanford prior to completing her fellowship in minimally invasive surgery at Washington University in St. Louis. She stayed on faculty at Washington University for three years prior to moving back to Stanford in 2019.During the pandemic, Dr. Salles has served as a disaster relief physician, caring for patients with COVID in the ICU. Dr. Salles obtained a PhD in education from Stanford University during her residency training, and her research focuses on gender equity, implicit bias, diversity, inclusion, and physician well-being. Her R01 grant from the NIH focuses on sexual harassment. She is a sought-after speaker and has given over 100 national and international invited talks related to gender equity, physician well-being, and weight bias. She currently serves as the Special Advisor for DEI Programs at the Stanford University Department of Medicine where she is a Clinical Associate Professor.

  • Atulkumar T. Shah, MD

    Atulkumar T. Shah, MD

    Clinical Assistant Professor, Medicine - Gastroenterology & Hepatology

    BioDr. Shah is a board-certified, fellowship-trained gastroenterologist with Stanford Health Care’s Digestive Health program. He is a clinical associate professor of medicine in the division of Gastroenterology and Hepatology at Stanford University School of Medicine.

    Dr. Shah treats all gastrointestinal and liver conditions, such as gastroesophageal reflux disease (GERD), colon polyps, hepatitis, inflammatory bowel disease, and irritable bowel syndrome. He has a special interest in the increasingly prevalent fatty liver disease, which allows him to work closely with patients to educate them about symptom management and making lifestyle changes that will improve their health and wellbeing.

    Dr. Shah treats all gastrointestinal and liver conditions, such as gastroesophageal reflux disease (GERD), colon polyps, hepatitis, inflammatory bowel disease, and irritable bowel syndrome. He has a special interest in the increasingly prevalent fatty liver disease, which allows him to work closely with patients to educate them about symptom management and making lifestyle changes that will improve their health and wellbeing.

    After more than two decades of practice, Dr. Shah added training in liver transplant to expand his knowledge of liver disease and offer his patients a “one-stop” resource for truly comprehensive care.

    Dr. Shah is a member of the American College of Gastroenterology, American Society of Gastrointestinal Endoscopy, and American Association for the Study of Liver Disease.

    Among Dr. Shah’s current research interests is the development of an algorithm assessing the impact of gastrointestinal disease management on readmission rates.

    Dr. Shah brings a personalized approach to working with patients and to teaching the next generation of physician scientists the classic skills of careful listening and patient examination. Throughout his career, he has emphasized the fundamental importance of balancing scientific expertise with empathy and compassion.

    As a volunteer with the non-profit organization Health Volunteers Overseas, Dr. Shah travels around the world to train physicians about liver disease management and treatment. He is director of the HVO site in Bangalore, India.

  • Edward Sheen

    Edward Sheen

    Adjunct Professor, Medicine - Med/Gastroenterology and Hepatology

    BioDr. Edward Sheen is Chief Quality and Population Health Executive for L.A. Care. Serving more than 2.9 million members, L.A. Care is the largest publicly operated health plan in the country. As a public entity, its mission is to provide access to quality care for vulnerable and low-income communities and to elevate the safety net. Previously, he was Chief Population Health Officer, Senior Vice President for Health Catalyst and Chief Medical Officer, Market Development and Solution Design for Lumeris, a leading value-based care technology and services operator as well as 5.0 Star Medicare Advantage plan. He has worked with health systems and payers across the country to improve health outcomes, enhance patient experience, strengthen care provider engagement, reduce costs of care, and accelerate their journey towards accountable care. He is dedicated to achieving accessible, equitable, person-centered, and high-performing care for all.

    Dr. Sheen’s experience has bridged the public, private, non-profit, and academic sectors and additionally includes work with Stanford University, the White House, U.S. Department of Defense, U.S. Department of Health and Human Services, California State Assembly, Kaiser Family Foundation, Blue Shield, California and American Medical Associations, and Genzyme. In 2014, he was one of 15 Americans appointed by President Obama a nonpartisan White House Fellow. He subsequently served as a Special Assistant to the Secretary of Defense and Defense Department senior health policy advisor and was a recipient of the Office of the Secretary of Defense Medal for Exceptional Public Service. Dr. Sheen was a Term Member of the Council on Foreign Relations. He currently serves on the National Advisory Council on the National Health Service Corps, which advises the Secretary of Health and Human Services. He is Adjunct Professor of Medicine and Global Health Faculty Fellow at Stanford. He has a long-standing active commitment to mentoring, teaching, and medical education.

    Dr. Sheen completed his Internal Medicine and Gastroenterology training at Stanford, received his MD from the University of California, San Francisco, and earned his MBA and MPH through scholarships from Stanford Graduate School of Business and Harvard School of Public Health, where he was also a Harvard Kennedy School Center for Public Leadership Zuckerman Fellow. He graduated magna cum laude from Brown University with a B.A. in Public Policy and induction into Phi Beta Kappa.

  • Gulshan Singh

    Gulshan Singh

    Postdoctoral Scholar, Gastroenterology

    Current Research and Scholarly InterestsMy current research interest is to understand the host-microbial pathways in intestinal inflammation. I am working to explore cellular heterogeneity at single immune cell level in systemic and local regions of the intestine that are associated with different Inflammatory bowel disease conditions.

  • Sundeep Singh

    Sundeep Singh

    Clinical Associate Professor, Medicine - Gastroenterology & Hepatology

    BioAfter living and training throughout the country, I am excited to be part of the Stanford team. As a result of both my personal experiences and training, I am passionate about ensuring that patients receive appropriate diagnostic testing and treatment options in order to improve people's quality of life. In collaboration with my amazing colleagues, I am confident in the high quality and easily accessible care we are able to provide to patients across northern California.

    While my interest is most in inflammatory bowel disease, I am also interested in the interaction between mental health, incentives, and emerging therapies in gastroenterology.

  • Sidhartha Sinha

    Sidhartha Sinha

    Assistant Professor of Medicine (Gastroenterology and Hepatology)

    Current Research and Scholarly InterestsThere are two primary and overlapping emphases of my research, both of which are driven and united by needs-based innovation and translational potential:

    (1) Understanding the microenvironment of the inflamed versus normal gut in order to identify better therapeutic targets for people with immune-¬mediated GI disorders. Here, our investigations include understanding the influence and interactions of pharmacologic and dietary interventions on gut microbiome/metabolomic changes and the host immune response. In the context of providing patients with new understanding and solutions for their disease, I have led and advised on the design of both pilot and large clinical trials (including new FDA approved therapies) for anti-inflammatory therapies;

    (2) Applying novel approaches and technologies (including natural language processing, computer vision, and reinforcement learning) to identify and address unmet clinical needs. In this area we have ongoing and published efforts in my lab to validate and develop solutions to pressing clinical needs. We have developed/led new drug delivery technologies with a multidisciplinary team that have shown strong potential in ongoing human IBD clinical trials. My lab has utilized both supervised and unsupervised approaches to analyze social media discourse and unstructured data sets for identifying patient needs that are rarely addressed in clinical settings. We have gained insights into patient perceptions around preventative health interventions, such as health screening and diet, including the dearth of evidence-based dietary recommendations to treat IBD (despite strong patient desire for solutions in this domain).